Dr. Garrett Lawlor, M.D

NPI: 1386874972
Total Payments
$251,435
2022 Payments
$2,434
Companies
22
Transactions
308
Medicare Patients
91
Medicare Billing
$13,911

Payment Breakdown by Category

Research$199,405 (79.3%)
Other$34,375 (13.7%)
Food & Beverage$6,895 (2.7%)
Travel$6,371 (2.5%)
Consulting$4,385 (1.7%)
Education$3.85 (0.0%)

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $199,405 7 79.3%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $30,775 10 12.2%
Food and Beverage $6,895 265 2.7%
Travel and Lodging $6,371 22 2.5%
Consulting Fee $4,385 2 1.7%
Honoraria $3,600 1 1.4%
Education $3.85 1 0.0%

Payments by Type

Research
$199,405
7 transactions
General
$52,031
301 transactions

Top Paying Companies

Company Total Records Latest Year
Eli Lilly and Company $199,231 3 $0 (2021)
Merck Sharp & Dohme Corporation $22,233 41 $0 (2020)
AbbVie Inc. $14,976 59 $0 (2021)
PFIZER INC. $7,166 38 $0 (2021)
E.R. Squibb & Sons, L.L.C. $2,905 10 $0 (2022)
Celgene Corporation $2,046 24 $0 (2022)
Janssen Biotech, Inc. $781.27 28 $0 (2022)
Salix Pharmaceuticals, a division of Bausch Health US, LLC $465.36 26 $0 (2021)
Takeda Pharmaceuticals U.S.A., Inc. $398.17 17 $0 (2020)
UCB, Inc. $275.93 11 $0 (2019)

Payment History by Year

Year Amount Transactions Top Company
2022 $2,434 27 Celgene Corporation ($1,780)
2021 $1,526 19 Eli Lilly and Company ($978.72)
2020 $162,553 41 Eli Lilly and Company ($155,922)
2019 $43,942 77 Eli Lilly and Company ($42,330)
2018 $23,006 76 Merck Sharp & Dohme Corporation ($21,918)
2017 $17,975 68 AbbVie, Inc. ($14,142)

All Payment Transactions

308 individual payment records from CMS Open Payments — Page 1 of 13

Date Company Product Nature Form Amount Type
12/03/2022 E.R. Squibb & Sons, L.L.C. Food and Beverage Cash or cash equivalent $101.00 General
12/03/2022 E.R. Squibb & Sons, L.L.C. Food and Beverage Cash or cash equivalent $60.00 General
12/03/2022 E.R. Squibb & Sons, L.L.C. Food and Beverage Cash or cash equivalent $30.00 General
11/03/2022 E.R. Squibb & Sons, L.L.C. Travel and Lodging Cash or cash equivalent $163.00 General
11/01/2022 E.R. Squibb & Sons, L.L.C. Food and Beverage Cash or cash equivalent $120.00 General
11/01/2022 E.R. Squibb & Sons, L.L.C. Food and Beverage Cash or cash equivalent $59.00 General
11/01/2022 E.R. Squibb & Sons, L.L.C. Food and Beverage Cash or cash equivalent $43.00 General
11/01/2022 E.R. Squibb & Sons, L.L.C. Food and Beverage Cash or cash equivalent $30.00 General
11/01/2022 E.R. Squibb & Sons, L.L.C. Food and Beverage Cash or cash equivalent $24.00 General
10/08/2022 Celgene Corporation ZEPOSIA (Drug) Food and Beverage Cash or cash equivalent $124.99 General
Category: Neuroscience
10/08/2022 Celgene Corporation ZEPOSIA (Drug) Food and Beverage Cash or cash equivalent $59.99 General
Category: Neuroscience
10/08/2022 Celgene Corporation ZEPOSIA (Drug) Food and Beverage Cash or cash equivalent $49.99 General
Category: Neuroscience
10/08/2022 Celgene Corporation ZEPOSIA (Drug) Food and Beverage Cash or cash equivalent $14.99 General
Category: Neuroscience
10/08/2022 Celgene Corporation ZEPOSIA (Drug) Food and Beverage Cash or cash equivalent $14.99 General
Category: Neuroscience
10/07/2022 Celgene Corporation ZEPOSIA (Drug) Travel and Lodging Cash or cash equivalent $315.27 General
Category: Neuroscience
09/30/2022 Celgene Corporation Food and Beverage Cash or cash equivalent $50.00 General
09/30/2022 Celgene Corporation Food and Beverage Cash or cash equivalent $50.00 General
09/30/2022 Celgene Corporation Food and Beverage Cash or cash equivalent $30.00 General
09/30/2022 Celgene Corporation Food and Beverage Cash or cash equivalent $30.00 General
09/29/2022 Celgene Corporation Travel and Lodging Cash or cash equivalent $383.13 General
06/10/2022 Celgene Corporation ZEPOSIA (Drug) Travel and Lodging Cash or cash equivalent $181.26 General
Category: Neuroscience
06/10/2022 Celgene Corporation ZEPOSIA (Drug) Food and Beverage Cash or cash equivalent $49.97 General
Category: Neuroscience
06/10/2022 Celgene Corporation ZEPOSIA (Drug) Food and Beverage Cash or cash equivalent $49.97 General
Category: Neuroscience
06/10/2022 Celgene Corporation ZEPOSIA (Drug) Food and Beverage Cash or cash equivalent $29.96 General
Category: Neuroscience
06/10/2022 Celgene Corporation ZEPOSIA (Drug) Food and Beverage Cash or cash equivalent $29.96 General
Category: Neuroscience

Research Studies & Clinical Trials

Study Name Company Amount Records
A PHASE 3, MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS LUCENT 3 Eli Lilly and Company $198,252 2
AN ADAPTIVE PHASE 2, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LY3471851 (NKTR 358) IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS Eli Lilly and Company $978.72 1
M16-009 AbbVie, Inc. $174.09 4

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2021 1 32 43 $27,950 $4,352
2020 2 59 94 $61,850 $9,559
Total Patients
91
Total Services
137
Medicare Billing
$13,911
Procedure Codes
3

All Medicare Procedures & Services

3 procedure records from CMS Medicare Utilization

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
99214 Established patient outpatient visit, total time 30-39 minutes Office 2021 32 43 $27,950 $4,352 15.6%
99214 Established patient office or other outpatient, visit typically 25 minutes Office 2020 44 79 $51,350 $7,267 14.2%
99204 New patient office or other outpatient visit, typically 45 minutes Office 2020 15 15 $10,500 $2,292 21.8%

About Dr. Garrett Lawlor, M.D

Dr. Garrett Lawlor, M.D is a Gastroenterology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/17/2009. The National Provider Identifier (NPI) number assigned to this provider is 1386874972.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Garrett Lawlor, M.D has received a total of $251,435 in payments from pharmaceutical and medical device companies, with $2,434 received in 2022. These payments were reported across 308 transactions from 22 companies. The most common payment nature is "" ($199,405).

As a Medicare-enrolled provider, Lawlor has provided services to 91 Medicare beneficiaries, totaling 137 services with total Medicare billing of $13,911. Data is available for 2 years (2020–2021), covering 3 distinct procedure/service records.

Practice Information

  • Specialty Gastroenterology
  • Location New York, NY
  • Active Since 07/17/2009
  • Last Updated 03/25/2015
  • Taxonomy Code 207RG0100X
  • Entity Type Individual
  • NPI Number 1386874972

Products in Payments

  • RENFLEXIS (Biological) $17,599
  • Humira (Biological) $7,137
  • XELJANZ (Drug) $4,229
  • ZEPOSIA (Drug) $1,479
  • INFLECTRA (Biological) $826.64
  • STELARA (Biological) $761.13
  • Entyvio (Biological) $549.03
  • XIFAXAN (Drug) $304.58
  • Cimzia (Drug) $275.93
  • XIFAXANIBSD (Drug) $266.20
  • DIFICID (Drug) $249.21
  • VIBERZI (Drug) $165.10
  • Mavyret (Drug) $144.35
  • LINZESS (Drug) $140.72
  • HUMIRA (Biological) $134.35
  • Viekira (Drug) $118.31
  • ZEPATIER (Drug) $112.49
  • Trulance (Drug) $91.22
  • GATTEX (Drug) $60.66
  • Sucraid (Drug) $31.71

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Gastroenterology Doctors in New York